News

Yahoo Finance14d
Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight
According to DelveInsight's analysis, the market size for Friedreich's ataxia is anticipated to surge at a significant rate by 2034. The prevalence of Friedreich's ataxia in the United States has ...
Yahoo Finance15d
Biogen Disappointed by INESSS Recommendation on SKYCLARYS™ and its Impact on Quebec Patients with Friedreich Ataxia
TORONTO, June 5, 2025 /CNW/ - Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with ...
Investing16d
Design Therapeutics starts Friedreich ataxia patient trial
CARLSBAD, Calif. - Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology firm with a market capitalization of $228 million, has announced the initiation of a clinical trial for ...
Investing16d
Design Therapeutics starts Friedreich ataxia patient trial
Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology firm with a market capitalization of $228 million, has announced the initiation of a clinical trial for Friedreich ataxia ...
Mena FN16d
Design Therapeutics Announces Start Of Friedreich Ataxia Patient Dosing Ex-U.S. In Its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial Of DT-216P2
today announced that the first Friedreich ataxia (FA) patient has been dosed via intravenous (IV) infusion in its RESTORE-FA (Reactivating Expression Suppressed Through Overcoming Repeat Expansion ...
manilatimes16d
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
June 04, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that ...